CAI
Caris Life Sciences, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-03
Figures on this page computed 2026-11-08 12:40 UTC
Last close
25.23USD
Market data, 2026-11-06
Except where said otherwise: 10-K for 2025, filed 2026-03-03
n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0002019410-26-000016
- Reported in
- USD
- computed
- 10-K for 2025, filed 2026-03-03
21.6%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0002019410-26-000016
- Reported in
- USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-11-04
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
-8.4%Net margin
Net Income / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0002019410-26-000016
- Reported in
- USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
8.2%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0002019410-26-000016
- Reported in
- USD
- 10-K for 2025, filed 2026-03-03
- 10-K for 2025, filed 2026-03-03
0.74Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Fiscal year
- 2025
- Accession
- 0002019410-26-000016
- Reported in
- USD
- 10-K for 2025, filed 2026-03-03
- 10-Q for 2025, filed 2026-11-04
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
- Source
- computed
- Taken on
- 2026-11-07
- Reported in
- USD
- computed
Price is the furthest below its sector's middle: 0.08 against 0.36 on the market's range.
- Growth22.5%80 of 100, above its sector
- Returns on capital21.6%51 of 100, above its sector
- Margins5.6%52 of 100, above its sector
- Price12.3x8 of 100, below its sector
- Safety0.7456 of 100, below its sector
- What it pays outn/anot placed
- What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.
Against its rival
lens 4 of 9Measure by measure
behind on 2 of 2- Profit on each unit of sales-8.4%-0.2%Behind
Higher is better here.
- Return on the capital it uses21.6%n/an/a
Higher is better here.
- Sales growth over five years22.5%56.6%Behind
Higher is better here.
- Debt against equity0.74n/an/a
Lower is better here.
- Gross marginn/an/an/a
Higher is better here.
- Price against earningsn/an/an/a
Lower is better here.
The first column is this company and the second is the one it is set against. A measure only one of the two reports is left at n/a rather than counted as a win.
Against Arrowhead Pharmaceuticals, Inc., CAI is behind on 2 of 2 measures.
Against Arrowhead Pharmaceuticals, Inc., CAI is behind on 2 of 2 measures.
Every figure in this lens
Except where said otherwise: 10-K for 2025, filed 2026-03-03
Profit on each unit of sales-8.4%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0002019410-26-000016
- Reported in
- USD
Return on the capital it uses21.6%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0002019410-26-000016
- Reported in
- USD
Sales growth over five years22.5%
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0002019410-26-000016
- Reported in
- USD
Debt against equity0.74
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0002019410-26-000016
- Reported in
- USD
Gross marginn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0002019410-26-000016
- Reported in
- USD
Price against earningsn/a
Not held.
- Source
- filed
- Statement
- income
- Fiscal year
- 2025
- Accession
- 0002019410-26-000016
- Reported in
- USD